Summary
This report details the use of the free-beam Nd: YAG laser alone and in combination with contact vaporization for treatment of benign prostatic hyperplasia. Improvements in urinary flow rates and symptoms were noted along with a high degree of patient satisfaction. The portable KTP/Nd:YAG laser wavelengths and the variety of optical fiber configurations provide versatility to the surgeon. This study further supports the use of laser energy as a means to treat urinary outflow obstruction from prostatic enlargement in selected cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barry MJ (1990) Medical outcomes, research and benign prostatic hyperplasia. Prostate [Suppl] 3:61–74
Holtgrewe HL, Mebust WK, Dowd JB, Cockett ATK, Peters PC, Proctor C (1989) Transurethral prostatectomy: Practice aspects of the dominant operation in American urology. J Urol 141:248–253
Arrhigi HM, Guess HA, Metter EJ, Fozard JL (1990) Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 16:253–261
McCarthy ME, Willard M (1990) Health care prostate therapies. Shearson, Lehman, and Hutton, pp 1–12
Johnson DE, Price RE, Cromeens DM (1992) Pathologic changes occurring in the prostate following transurethral laser prostatectomy. Lasers Surg Med 12:254–263
Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J (1992) Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 69:603–608
Kabalin JN (1993) Laser prostatectomy performed with a right angle firing neodymium: YAG laser fiber at 40 watts power setting. J Urol 150:95–99
Stern M (1926) Resections of obstructions at the vesical orifice: new instruments and new method. JAMA 87:1726–1727
Benign Prostatic Hyperplasia Guideline Panel (1994) Cost of treatment. In: Benign prostatic hyperplasia diagnosis and treatment. Publication 94–0582. Agency for Health Care Policy and Research, Rockville, Maryland, pp 129–130
McPhee MS (1986) Lasers in the treatment of cancer of the prostate: an overview. Biomed Pharmacother 40:321–322
Motamedi M, Cammack JT, Torres JH, Anvari B, Orihuela E, Cowan D, Warren MM (1993) Laser coagulation of the prostate: methodology and dosimetry considerations (abstract 317). Lasers Surg Med 13 [Suppl 5]:65
Kabalin JN, Gill H (1994) Dosimetry studies utilizing the Urolase right angle firing neodymium:YAG laser fiber. Lasers Surg Med 14:145–154
Kabalin JN (1993) Urolase laser prostatectomy. Monogr Urol 14:23–36
Smith JA Jr. Dixon JA (1984) Laser photoradiation in urologic surgery. J Urol 131:631–635
Norris JP, Norris DM, Lee RD, Rubenstein MA (1993) Visual laser ablation of the prostate: clinical experience in 108 patients. J Urol 150:1612–1614
O'Leary MP, Barry MJ, Fowler FJ Jr (1992) Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol 148:1546–1548
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, the Measurement Committee of the American Urological Association (1992) American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549–1557
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manyak, M.J., Aulisi, G.P. Free-beam and contact laser ablation of benign prostatic hyperplasia with the KTP/Nd:YAG laser: efficacy and versatility. World J Urol 13, 104–108 (1995). https://doi.org/10.1007/BF00183623
Issue Date:
DOI: https://doi.org/10.1007/BF00183623